Claims
- 1. An isolated polypeptide consisting essentially of an amino acid sequence selected from the group consisting of:
(a) an amino acid sequence selected from the group consisting of:
(a1) amino acids Xaa1 through Xaa2 of SEQ ID NO: 6, wherein Xaa1 is an amino acid selected from the group consisting of amino acids 20 through 42 of SEQ ID NO: 6 and Xaa2 is an amino acid selected from the group consisting of amino acids 192 through 213 of SEQ ID NO: 6; (a2) amino acids 20 through 192 of SEQ ID NO: 6; (a3) amino acids 20 through 194 of SEQ ID NO: 6; (a4) amino acids 20 through 205 of SEQ ID NO: 6; (a5) amino acids 20 through 213 of SEQ ID NO: 6; (a6) amino acids 34 through 192 of SEQ ID NO: 6; (a7) amino acids 34 through 194 of SEQ ID NO: 6; (a8) amino acids 34 through 205 of SEQ ID NO: 6; (a9) amino acids 34 through 213 of SEQ ID NO: 6; (a10) amino acids 42 through 192 of SEQ ID NO: 6; (a11) amino acids 42 through 194 of SEQ ID NO: 6; (a12) amino acids 42 through 205 of SEQ ID NO: 6; and (a13) amino acids 42 through 213 of SEQ ID NO: 6; (b) an amino acid sequence selected from the group consisting of:
(b1) amino acids 1 through 220 of SEQ ID NO: 6; (b2) amino acids 14 through 220 of SEQ ID NO: 6 (b3) amino acids 15 through 220 of SEQ ID NO: 6; (b4) amino acids 17 through 220 of SEQ ID NO: 6; (b5) amino acids Xaa3 through Xaa4 of SEQ ID NO: 6, wherein Xaa3 is an amino acid selected from the group consisting of amino acids 20 through 42 of SEQ ID NO: 6 and Xaa4 is an amino acid selected from the group consisting of amino acids 102 through 126 of SEQ ID NO: 6; (b6) amino acids 20 through 102 of SEQ ID NO: 6 (b7) amino acids 20 through 109 of SEQ ID NO: 6; (b8) amino acids 20 through 120 of SEQ ID NO: 6; (b9) amino acids 20 through 126 of SEQ ID NO: 6 (b10) amino acids 34 through 102 of SEQ ID NO: 6; (b11) amino acids 34 through 109 of SEQ ID NO: 6; (b12) amino acids 34 through 120 of SEQ ID NO: 6 (b13) amino acids 34 through 126 of SEQ ID NO: 6; (b14) amino acids 42 through 102 of SEQ ID NO: 6; (b15) amino acids 42 through 109 of SEQ ID NO: 6 (b16) amino acids 42 through 120 of SEQ ID NO: 6; (b17) amino acids 42 through 126 of SEQ ID NO: 6; (b18) amino acids Xaa5 through Xaa6 of SEQ ID NO: 6, wherein Xaa5 is an amino acid selected from the group consisting of amino acids 127 through 143 of SEQ ID NO: 6 and Xaa6 is an amino acid selected from the group consisting of amino acids 192 through 213 of SEQ ID NO: 6; (b19) amino acids 127 through 192 of SEQ ID NO: 6 (b20) amino acids 127 through 194 of SEQ ID NO: 6; (b21) amino acids 127 through 205 of SEQ ID NO: 6; (b22) amino acids 127 through 213 of SEQ ID NO: 6 (b23) amino acids 132 through 192 of SEQ ID NO: 6; (b24) amino acids 132 through 194 of SEQ ID NO: 6; (b25) amino acids 132 through 205 of SEQ ID NO: 6 (b26) amino acids 132 through 213 of SEQ ID NO: 6; (b27) amino acids 134 through 192 of SEQ ID NO: 6; (b28) amino acids 134 through 194 of SEQ ID NO: 6 (b29) amino acids 134 through 205 of SEQ ID NO: 6; (b30) amino acids 134 through 213 of SEQ ID NO: 6; (b31) amino acids 143 through 192 of SEQ ID NO: 6 (b32) amino acids 143 through 194 of SEQ ID NO: 6; (b33) amino acids 143 through 205 of SEQ ID NO: 6; (b34) amino acids 143 through 213 of SEQ ID NO: 6 (b35) amino acids 221 through 240 of SEQ ID NO: 6; and (b36) amino acids 241 through 273 of SEQ ID NO: 6; (c) a fragment of the amino acid sequences of any of (a)-(b) comprising at least 20 contiguous amino acids, wherein said fragment binds to a T cell receptor; (d) an amino acid sequence comprising at least 30 amino acids and sharing amino acid identity with the amino acid sequences of any of (a)-(b), wherein the percent amino acid identity is selected from the group consisting of: at least 95%, at least 97.5%, at least 99%, and at least 99.5%; and (e) an amino acid sequence of (d), wherein a polypeptide comprising said amino acid sequence of (d) binds to an antibody that also binds to a polypeptide comprising an amino acid sequence of any of (a)-(c).
- 2. An isolated nucleic acid encoding a polypeptide of claim 1.
- 3. The nucleic acid of claim 2 consisting essentially of a nucleotide sequence selected from the group consisting of:
(a) SEQ ID NO: 4; (b) a nucleotide sequence selected from the group consisting of:
(b1) nucleotides N1 through N2 of SEQ ID NO: 4, wherein N1 is a nucleotide selected from the group consisting of nucleotides 329 through 395 of SEQ ID NO: 4 and N2 is a nucleotide selected from the group consisting of nucleotides 847 through 910 of SEQ ID NO: 4; (b2) nucleotides 329 through 847 of SEQ ID NO: 4; (b3) nucleotides 329 through 853 of SEQ ID NO: 4; (b4) nucleotides 329 through 886 of SEQ ID NO: 4; (b5) nucleotides 329 through 910 of SEQ ID NO: 4; (b6) nucleotides 371 through 847 of SEQ ID NO: 4; (b7) nucleotides 371 through 853 of SEQ ID NO: 4; (b8) nucleotides 371 through 886 of SEQ ID NO: 4; (b9) nucleotides 371 through 910 of SEQ ID NO: 4; (b10) nucleotides 395 through 847 of SEQ ID NO: 4; (b11) nucleotides 395 through 853 of SEQ ID NO: 4; (b12) nucleotides 395 through 886 of SEQ ID NO: 4; and (b13) nucleotides 395 through 910 of SEQ ID NO: 4; (c) an nucleotide sequence selected from the group consisting of:
(c1) nucleotides 272 through 931 of SEQ ID NO: 4; (c2) nucleotides 311 through 931 of SEQ ID NO: 4 (c3) nucleotides 314 through 931 of SEQ ID NO: 4; (c4) nucleotides 320 through 931 of SEQ ID NO: 4; (c5) nucleotides N3 through N4 of SEQ ID NO: 4, wherein N3 is a nucleotide selected from the group consisting of nucleotides 329 through 395 of SEQ ID NO: 4 and N4 is a nucleotide selected from the group consisting of nucleotides 577 through 649 of SEQ ID NO: 4; (c6) nucleotides 329 through 577 of SEQ ID NO: 4 (c7) nucleotides 329 through 598 of SEQ ID NO: 4; (c8) nucleotides 329 through 631 of SEQ ID NO: 4; (c9) nucleotides 329 through 649 of SEQ ID NO: 4 (c10) nucleotides 371 through 577 of SEQ ID NO: 4; (c11) nucleotides 371 through 598 of SEQ ID NO: 4; (c12) nucleotides 371 through 631 of SEQ ID NO: 4 (c13) nucleotides 371 through 649 of SEQ ID NO: 4; (c14) nucleotides 395 through 577 of SEQ ID NO: 4; (c15) nucleotides 395 through 598 of SEQ ID NO: 4 (c16) nucleotides 395 through 631 of SEQ ID NO: 4; (c17) nucleotides 395 through 649 of SEQ ID NO: 4; (c18) nucleotides N5 through N6 of SEQ ID NO: 4, wherein N5 is a nucleotide selected from the group consisting of nucleotides 650 through 698 of SEQ ID NO: 4 and N6 is a nucleotide selected from the group consisting of nucleotides 847 through 910 of SEQ ID NO: 4; (c19) nucleotides 650 through 847 of SEQ ID NO: 4 (c329) nucleotides 650 through 853 of SEQ ID NO: 4; (c21) nucleotides 650 through 886 of SEQ ID NO: 4; (c22) nucleotides 650 through 910 of SEQ ID NO: 4 (c23) nucleotides 665 through 847 of SEQ ID NO: 4; (c24) nucleotides 665 through 853 of SEQ ID NO: 4; (c25) nucleotides 665 through 886 of SEQ ID NO: 4 (c26) nucleotides 665 through 910 of SEQ ID NO: 4; (c27) nucleotides 671 through 847 of SEQ ID NO: 4; (c28) nucleotides 671 through 853 of SEQ ID NO: 4 (c29) nucleotides 671 through 886 of SEQ ID NO: 4; (c30) nucleotides 671 through 910 of SEQ ID NO: 4; (c31) nucleotides 698 through 847 of SEQ ID NO: 4 (c32) nucleotides 698 through 853 of SEQ ID NO: 4; (c33) nucleotides 698 through 886 of SEQ ID NO: 4; (c371) nucleotides 698 through 910 of SEQ ID NO: 4 (c35) nucleotides 932 through 991 of SEQ ID NO: 4; and (c36) nucleotides 992 through 1090 of SEQ ID NO: 4; and (d) allelic variants of (a)-(c).
- 4. An isolated genomic nucleic acid corresponding to the nucleic acid of claim 2.
- 5. An expression vector comprising at least one nucleic acid according to claim 2.
- 6. A recombinant host cell comprising at least one nucleic acid according to claim 2.
- 7. A process for producing a polypeptide encoded by the nucleic acid of claim 2, comprising culturing a recombinant host cell under conditions promoting expression of said polypeptide, wherein the recombinant host cell comprises at least one nucleic acid according to claim 2.
- 8. The polypeptide produced by the process of claim 7.
- 9. An isolated antibody that binds to the polypeptide of claim 8.
- 10. An isolated antibody that inhibits the T cell receptor binding activity of the polypeptide of claim 8.
- 11. A method for treating an immunological condition comprising administering at least one compound selected from the group consisting of the polypeptide of claim 8 and agonists of said polypeptide; wherein the immunological condition is selected from the group consisting of transplant rejection; graft-versus-host disease; allergy; asthma; inflammatory bowel disease (IBD); sepsis; diseases that are caused or exacerbated by T cell mediated inflammation, such as Alzheimer's disease and atherosclerosis; and autoimmune diseases such as systemic lupus erythematosus (SLE or lupus), Grave's disease, psoriasis, autoimmune demyelination, multiple sclerosis, autoimmune diabetes and diabetic neuropathy, and rheumatoid arthritis.
- 12. A method for treating an immunological condition comprising administering an antagonist of the polypeptide of claim 8; wherein the immunological condition is selected from the group consisting of cancer, including metastasis of cancer cells; bacterial or viral infections, including HIV infection; delayed reconstitution of T cells, for example following bone marrow transplantation; defects in T cell or accessory cell function, for example in hemodialysis patients subject to renal failure; and congenital immunodeficiencies.
- 13. A composition comprising an antigen and at least one compound selected from the group consisting of the polypeptide of claim 8 and agonists of said polypeptide.
- 14. A method of enhancing an immune tolerance inducing response by administering the composition of claim 13.
- 15. A composition comprising an antigen and an antagonist of the polypeptide of claim 8.
- 16. A method of enhancing an immune response by administering the composition of claim 15.
- 17. An isolated polypeptide consisting essentially of amino acids 34 through 109 of SEQ ID NO: 6.
- 18. An isolated polypeptide consisting essentially of an amino acid sequence selected from the group consisting of:
a) SEQ ID NO: 13; b) a fragment of SEQ ID NO: 13, wherein the fragment comprises a contiguous amino acid sequence of SEQ ID NO: 13 including the pair of conserved cysteine residues at amino acids 29 and 103 of SEQ ID NO: 13; c) a fragment of SEQ ID NO: 13 comprising at least 20 contiguous amino acids, wherein the fragment binds to a T cell receptor; and d) an amino acid sequence comprising at least 20 amino acids and sharing amino acid identity with the amino acid sequences of any of (a)-(c), wherein the percent amino acid identity is selected from the group consisting of: at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 99%, and at least 99.5%.
- 19. An isolated antibody that inhibits the T cell receptor binding activity of the polypeptide of claim 18.
- 20. A method for treating an immunological condition comprising administering at least one compound selected from the group consisting of the polypeptide of claim 18 and agonists of said polypeptide; wherein the immunological condition is selected from the group consisting of autoimmune diseases such as systemic lupus erythematosus (SLE or lupus), Grave's disease, psoriasis, autoimmune demyelination, multiple sclerosis, autoimmune diabetes and diabetic neuropathy, and rheumatoid arthritis
Parent Case Info
[0001] This application claims the benefit under 35 U.S.C. 119(e) of U.S. provisional applications Serial No. 60/260,617, filed Jan. 08, 2001; and Serial No. 60/262,737, filed Jan. 19, 2001; all of which are incorporated in their entirety by reference herein.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60260617 |
Jan 2001 |
US |
|
60262737 |
Jan 2001 |
US |